Table 4.
CTCAEv5 toxicity before and after dose reduction
| Side-effect | Before dose reduction at steady-state tamoxifen 20 mg (n = 17) n (%) |
3 months after dose reduction to tamoxifen 10 mg (n = 17) n (%) |
|
|---|---|---|---|
| CTCAE 1 | CTCAE 2 | CTCAE 1 | |
| Hot flashes | 13 (76) | 2 (12) | 12 (71) |
| Insomnia | 10 (59) | 1 (6) | 7 (41) |
| Mood alterations | 10 (59) | 0 | 4 (24) |
| Arthralgia | 7 (41) | 3 (18) | 8 (47) |
| Muscle cramp | 4 (24) | 0 | 4 (24) |
| Nausea | 2 (12) | 1 (6) | 1 (6) |
| Headache | 3 (18) | 0 | 1 (6) |
| Vaginal dryness | 3 (18) | 0 | 1 (6) |
| Fatigue | 2 (12) | 0 | 3 (18) |
| Dizziness | 2 (12) | 0 | 1 (6) |
| Weight gain | 2 (12) | 0 | 2 (12) |
| Chills | 1 (6) | 0 | 0 |
| Bloated feeling | 1 (6) | 0 | 0 |
| Obstipation | 1 (6) | 0 | 1 (6) |
| Alopecia | 1 (6) | 0 | 1 (6) |
| Dry mouth | 1 (6) | 0 | 0 |
| Anorexia | 1 (6) | 0 | 0 |
| Decreased libido | 1 (6) | 0 | 0 |
| Amnesia | 1 (6) | 0 | 0 |
| Increased appetite | 0 | 0 | 1 (6) |
| Anxiety | 0 | 0 | 1 (6) |
| Vaginal discharge | 0 | 0 | 1 (6) |
CTCAEv5, Common Terminology Criteria for Adverse Events version 5.